GPR132 and neuropathic pain: In a mouse neuropathic pain model, GPR132 deficiency significantly reduced hypersensitivity, immune cell infiltration, and proinflammatory cytokine release, suggesting that GPR132 inhibition may offer a novel therapeutic strategy [48].